<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00517010</url>
  </required_header>
  <id_info>
    <org_study_id>200715285</org_study_id>
    <secondary_id>100,481</secondary_id>
    <nct_id>NCT00517010</nct_id>
  </id_info>
  <brief_title>Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration</brief_title>
  <official_title>Phase 1 Pilot Open Label Prospective Observational Study of Safety and Tolerability of Lucentis Combined With Proton Beam Irradiation in Treating Exudative Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because a possible synergism of radiation and inhibitors of vascular endothelial growth
      factor has been shown in cancer patients and patients with wet macular degeneration, this
      pilot study is being conducted to determine whether treating wet macular degeneration with a
      combination of Lucentis and proton beam irradiation is safe. Lucentis is an inhibitor of
      vascular endothelial growth factor which was recently FDA approved for treatment of wet
      macular degeneration. It appears to be the most effective therapy thus far for wet macular
      degeneration among all drugs FDA approved for this condition. If no major safety issues are
      associated with this combination therapy, a larger study will be conducted to determine
      whether this combination therapy is more effective than Lucentis monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Five subjects diagnosed with wet macular degeneration will be treated with standard of care,
      i.e. intravitreal Lucentis injection monthly for the first four months and as needed
      thereafter. Within six weeks of the first Lucentis injection, the eye will also be treated
      with 24 Gy of proton beam divided into two fractions. Each subject will be followed for 2 yrs
      with monthly examination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Ocular Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Any ocular adverse event identified by eye examination during the study follow-up will be recorded and determined for possible or probable relation to study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Change in BCVA From Baseline</measure>
    <time_frame>24 months</time_frame>
    <description>change in number of letter read correctly in study eye compared to the number of letters read correctly at baseline, i.e. BCVA (number of letters read correctly) at 24 months minus BCVA (number of letters read correctly) at baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>proton beam with ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention is 24Gy proton radiation in 2 fractions given within 6 weeks of first dose of intravitreal ranibizumab (0.5mg) drug combined with four monthly doses of intravitreal lucentis and monthly prn lucentis thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proton beam irradiation and ranibizumab</intervention_name>
    <description>ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.</description>
    <arm_group_label>proton beam with ranibizumab</arm_group_label>
    <other_name>Lucentis and proton beam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age &gt; 50 years

          -  Patient related considerations

          -  Able to maintain follow-up for at least 24 months.

          -  Women must be postmenopausal without a period for at least one year.

          -  Hgb A1C &lt; 6

          -  Diagnosed with Age-related Macular Degeneration (ARMD) with active subfoveal choroidal
             neovascular membrane (CNVM), new or recurrent

          -  Visual acuity 20/60 to 20/400

          -  Lesion size &lt; 12 Disc Area

          -  Submacular hemorrhage less than 75% of total lesion

          -  Submacular fibrosis less than 25% of total lesion

          -  Candidate for intravitreal Lucentis

        Exclusion Criteria:

          -  Prior enrollment in the study

          -  Pregnancy (positive pregnancy test) or lactation

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated

          -  Participation in another simultaneous medical investigation or trial

          -  CNVM within 1 mm from the disc margin

          -  Photodynamic Therapy (PDT) within 3 months

          -  Anti-VEGF therapy within 6 weeks

          -  Intravitreal or subtenon's Kenalog within 6 months

          -  Intraocular surgery within 3 months or expected in the next 6 months

          -  Current or planned participation in other experimental treatments for wet AMD

          -  Other concurrent retinopathy or optic neuropathy

          -  Other causes of CNVM, i.e. myopic degeneration or ocular histoplasmosis (POHS)

          -  Significant media opacity precluding adequate view of the fundus for exam,

          -  photography or OCT

          -  History of radiation therapy to the head or study eye

          -  Systemic anticoagulation with coumadin

          -  Head tremor or h/o claustrophobia precluding positioning for proton irradiation

          -  Inability to maintain steady fixation with either eye

          -  Diabetes mellitus requiring treatment

          -  History of Malignancy treated within 5 years

          -  Allergy to Fluorescein dye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanna S Park, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Park SS, Daftari I, Phillips T, Morse LS. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration. Retina. 2012 May;32(5):956-66. doi: 10.1097/IAE.0b013e31822a8d6a.</citation>
    <PMID>22183743</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2007</study_first_submitted>
  <study_first_submitted_qc>August 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2007</study_first_posted>
  <results_first_submitted>December 2, 2015</results_first_submitted>
  <results_first_submitted_qc>June 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 11, 2016</results_first_posted>
  <last_update_submitted>June 28, 2016</last_update_submitted>
  <last_update_submitted_qc>June 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>Exudative age-related macular degeneration</keyword>
  <keyword>Wet macular degeneration</keyword>
  <keyword>Intravitreal injection</keyword>
  <keyword>Proton beam irradiation</keyword>
  <keyword>Lucentis</keyword>
  <keyword>Ranibizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Findings have been presented at national and international venues and published in scientific peer-reviewed journal</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://ovidsp.tx.ovid.com/sp-3.20.0b/ovidweb.cgi?QS2=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</doc_url>
      <doc_comment>Published data</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lucentis Combined With Proton Beam</title>
          <description>Proton beam irradiation and ranibizumab: ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lucentis Combined With Proton Beam</title>
          <description>Proton beam irradiation and ranibizumab: ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Best corrected visual acuity</title>
          <description>Number of letters read correctly</description>
          <units>logMAR best corrected visual acuity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.58" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Optical coherence tomography central macular thickness</title>
          <description>Central macular thickness for quantitative measure; qualitative measure of presence or absence of intraretinal or subretinal fluid</description>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="335" spread="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence and Severity of Ocular Adverse Events</title>
        <description>Any ocular adverse event identified by eye examination during the study follow-up will be recorded and determined for possible or probable relation to study treatment.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lucentis Combined With Proton Beam</title>
            <description>Proton beam irradiation and ranibizumab: ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Severity of Ocular Adverse Events</title>
          <description>Any ocular adverse event identified by eye examination during the study follow-up will be recorded and determined for possible or probable relation to study treatment.</description>
          <units>number of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1. Change in BCVA From Baseline</title>
        <description>change in number of letter read correctly in study eye compared to the number of letters read correctly at baseline, i.e. BCVA (number of letters read correctly) at 24 months minus BCVA (number of letters read correctly) at baseline</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lucentis Combined With Proton Beam</title>
            <description>Proton beam irradiation and ranibizumab: ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.</description>
          </group>
        </group_list>
        <measure>
          <title>1. Change in BCVA From Baseline</title>
          <description>change in number of letter read correctly in study eye compared to the number of letters read correctly at baseline, i.e. BCVA (number of letters read correctly) at 24 months minus BCVA (number of letters read correctly) at baseline</description>
          <units>change in number of letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lucentis Combined With Proton Beam</title>
          <description>Proton beam irradiation and ranibizumab: ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susanna Park MD PhD</name_or_title>
      <organization>University of California Davis</organization>
      <phone>916-734-6074</phone>
      <email>sscpark@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

